Previous 10 | Next 10 |
Insiders stepped up their buying last week. Notable Insider Buys: Teledyne Technologies Incorporated, B. Riley Financial, Inc., Intel Corporation, Guaranty Bancshares, Inc., and FuelCell Energy, Inc. Notable Insider Sells: Facebook, Inc., Guardant Health, Inc., Workhorse Group Inc...
Looking For The Best Biotech Stocks For Your Watchlist? 3 Names To Know While many investors would agree that 2020 was the year for biotech stocks to shine, we may be able to say the same for 2021. The industry continues to bring huge gains for investors. Evidently, we see this ...
Data Shows First-Line Testing with Guardant Health Liquid Biopsy Uncovers 23.6 Percent More Actionable Mutations Than with Tissue Biopsy Guardant Health, Inc . (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients w...
Insider buying decreased significantly last week. Notable Insider Buys: Driven Brands Holdings, Inc., Adverum Biotechnologies, Inc., Vector Group Ltd., HEICO Corporation, and Landec Corporation. Notable Insider Sells: Lemonade, Inc., Guardant Health, Inc., Facebook, Inc., Wayfair ...
With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL) , which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ:...
Epigenomics (EPGNF) has lost 24.8% after the company announced that U.S. Centers for Medicare & Medicaid Services (“CMS”) issued a negative reimbursement decision related to the National Coverage Determination (“NCD”) of Epi proColon, its blood test...
Guardant Health ([[GH]] -0.6%) have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using its proprietary digital sequencing platform, at Vall d’Hebron Institute of Oncology's ((VHIO)) facility in Barcelona, Spain.The service is expect...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, us...
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 Ame...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...